Javascript must be enabled to continue!
Abstract 1350: New NCI experimental therapeutics program (NExT) small molecule libraries for academic investigator hts projects
View through CrossRef
Abstract
The NCI Experimental Therapeutics Program (NExT) is making available two new smaller (3.5K) screening libraries suitable for academic investigator HTS drug discovery programs. The NExT program is a partnership between NCI's Division of Cancer Treatment and Diagnosis (DCTD) and the Center for Cancer Research (CCR). NExT consolidates NCI's anticancer drug discovery and development resources with the goal of maintaining a robust and balanced therapeutics pipeline. It encompasses tasks from new target validation through Phase III clinical trial evaluation. The Program is designed to streamline development and testing of promising new anticancer drugs and to expedite their delivery to the bedside. As part of the Program to support HTS drug discovery, NCI has previously offered academic oncology investigators access to our full 83K NExT Diversity Library in single-use, 384-well plate format. The set was designed to identify lead small molecules for drug discovery programs. We are now making available 2 smaller pre-plated subsets of this library, the NExT Diversity 3500 and NExT Diversity 3500 SAR, for when screening the full set is not appropriate. Each library contains 3,500 compounds: NExT Diversity 3500 is a diverse sampling across the entire 83K library while the NExT Diversity 3500 SAR is designed to facilitate rapid SAR follow-up by sampling only those compounds that have at least 5 close neighbors in the 83K library. The new libraries were designed by initially filtering the full NExT Diversity Library for undesirable compounds such as PAINS. Both atom-pair based 2D pharmacophore fingerprints and ECFP6 topological fingerprints from ChemAxon were then employed to generate the two non-overlapping subset libraries. The NExT screening libraries are provided as a resource to academic oncology investigators through the NExT Program (see NExT Resources: http://next.cancer.gov/). The design details and physiochemical characteristics of the two new sets, NExT Diversity 3500 and NExT 3500 SAR, and procedures and criteria for accessing this resource are presented along with several other screening sets available through the Developmental Therapeutics Program (DTP).
Citation Format: Raj N. Misra, Michael Eckert, Christian Laggner. New NCI experimental therapeutics program (NExT) small molecule libraries for academic investigator hts projects. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1350.
American Association for Cancer Research (AACR)
Title: Abstract 1350: New NCI experimental therapeutics program (NExT) small molecule libraries for academic investigator hts projects
Description:
Abstract
The NCI Experimental Therapeutics Program (NExT) is making available two new smaller (3.
5K) screening libraries suitable for academic investigator HTS drug discovery programs.
The NExT program is a partnership between NCI's Division of Cancer Treatment and Diagnosis (DCTD) and the Center for Cancer Research (CCR).
NExT consolidates NCI's anticancer drug discovery and development resources with the goal of maintaining a robust and balanced therapeutics pipeline.
It encompasses tasks from new target validation through Phase III clinical trial evaluation.
The Program is designed to streamline development and testing of promising new anticancer drugs and to expedite their delivery to the bedside.
As part of the Program to support HTS drug discovery, NCI has previously offered academic oncology investigators access to our full 83K NExT Diversity Library in single-use, 384-well plate format.
The set was designed to identify lead small molecules for drug discovery programs.
We are now making available 2 smaller pre-plated subsets of this library, the NExT Diversity 3500 and NExT Diversity 3500 SAR, for when screening the full set is not appropriate.
Each library contains 3,500 compounds: NExT Diversity 3500 is a diverse sampling across the entire 83K library while the NExT Diversity 3500 SAR is designed to facilitate rapid SAR follow-up by sampling only those compounds that have at least 5 close neighbors in the 83K library.
The new libraries were designed by initially filtering the full NExT Diversity Library for undesirable compounds such as PAINS.
Both atom-pair based 2D pharmacophore fingerprints and ECFP6 topological fingerprints from ChemAxon were then employed to generate the two non-overlapping subset libraries.
The NExT screening libraries are provided as a resource to academic oncology investigators through the NExT Program (see NExT Resources: http://next.
cancer.
gov/).
The design details and physiochemical characteristics of the two new sets, NExT Diversity 3500 and NExT 3500 SAR, and procedures and criteria for accessing this resource are presented along with several other screening sets available through the Developmental Therapeutics Program (DTP).
Citation Format: Raj N.
Misra, Michael Eckert, Christian Laggner.
New NCI experimental therapeutics program (NExT) small molecule libraries for academic investigator hts projects.
[abstract].
In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA.
Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1350.
Related Results
Romanya Cephesinde Osmanlı 6’ncı Kolordusu’nun Harp Sahası
Romanya Cephesinde Osmanlı 6’ncı Kolordusu’nun Harp Sahası
Osmanlı Devleti, Birinci Dünya Savaşı’nda sınırları dışında Romanya, Galiçya ve Makedonya cephelerinde İttifak devletlerine (Almanya, Avusturya-Macaristan ve Bulgaristan) insan güc...
Global Oncology Research and Training Collaborations Led by the National Cancer Institute (NCI)–Designated Cancer Centers: Results From the 2018 NCI/ASCO Global Oncology Survey of NCI-Designated Cancer Centers
Global Oncology Research and Training Collaborations Led by the National Cancer Institute (NCI)–Designated Cancer Centers: Results From the 2018 NCI/ASCO Global Oncology Survey of NCI-Designated Cancer Centers
PURPOSE The National Cancer Institute (NCI)–Designated Cancer Centers (NDCCs) are active in global oncology research and training, leading collaborations that contribute to the evi...
Efficient approximate string matching techniques for sequence alignment
Efficient approximate string matching techniques for sequence alignment
One of the outstanding milestones achieved in recent years in the field of biotechnology research has been the development of high-throughput sequencing (HTS). Due to the fact that...
Connectivity Index of Directed Rough Fuzzy Graphs
and its Application in Traffic Flow Network
Connectivity Index of Directed Rough Fuzzy Graphs
and its Application in Traffic Flow Network
Abstract
The directed rough fuzzy graph (DRFG) is a fusion of rough and fuzzy theory, because it
deals with incomplete and vague information simultaneously. Connection or t...
Current control and tuning in a closed HTS coil
Current control and tuning in a closed HTS coil
Up to today, a coil made of high temperature superconductor (HTS) usually needs a soldered joint to form a closed circuit. It is very difficult to have the joint fully superconduct...
Hot Tearing Susceptibility of Binary Mg–Gd Alloy Castings and Influence of Grain Refinement
Hot Tearing Susceptibility of Binary Mg–Gd Alloy Castings and Influence of Grain Refinement
The hot tearing susceptibility (HTS) of binary Mg–Gd alloys is tested from 1.0 to 8.0 wt% using a constrained rod casting (CRC) mold. It is found that the curve of the HTS versus G...
Overview of High Temperature Superconductor Machines
Overview of High Temperature Superconductor Machines
Electrical machines are important parts of different power systems. The application of high temperature superconductors (HTS) in electrical machines is very promising due to high t...
Abstract 3500: NCI's Provocative Questions Initiative
Abstract 3500: NCI's Provocative Questions Initiative
Abstract
In 2011, the NCI Director, Dr. Harold Varmus, created the Provocative Questions (PQ) initiative to encourage imaginative, bold approaches designed to tackle...

